{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT04384523: Phase 1 Interventional Completed Ascites Hepatic
(2019)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT04347382: Phase 3 Interventional Completed Coronavirus Infection
(2020)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
US Approved Allergenic Extract
(1998)
Source:
BLA103753
(1998)
Source URL:
First approved in 1998
Source:
BLA103753
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
US Approved Allergenic Extract
(1981)
Source:
BLA101833
(1981)
Source URL:
First approved in 1981
Source:
BLA101833
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
M017
(2019)
Source URL:
First approved in 2016
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE